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arls-University Tübingen,his study sought to evaluate the role of protease-activated receptor-2 (PAR2) in coxsackievirus B3 (CVB3)–induced
myocarditis.Background An infection with CVB3 leads to myocarditis. PAR2 modulates the innate immune response. Toll-like receptor-3
(TLR3) is crucial for the innate immune response by inducing the expression of the antiviral cytokine
interferon-beta (IFNb).Methods To induce myocarditis, wild-type (wt) and PAR2 knockout (ko) mice were infected with 105 plaque-forming units
CVB3. Mice underwent hemodynamic measurements with a 1.2-F microconductance catheter. Wt and PAR2ko
hearts and cardiac cells were analyzed for viral replication and immune response with plaque assay, quantitative
polymerase chain reaction, Western blot, and immunohistochemistry.Results Compared with wt mice, PAR2ko mice and cardiomyocytes exhibited a reduced viral load and developed no
myocarditis after infection with CVB3. Hearts and cardiac ﬁbroblasts from PAR2ko mice expressed higher basal
levels of IFNb than wt mice did. Treatment with CVB3 and polyinosinic:polycytidylic acid led to higher IFNb
expression in PAR2ko than in wt ﬁbroblasts and reduced virus replication in PAR2ko ﬁbroblasts was abrogated
by neutralizing IFNb antibody. Overexpression of PAR2 reduced the basal IFNb expression. Moreover, a direct
interaction between PAR2 and Toll-like receptor 3 was observed. PAR2 expression in endomyocardial biopsies
of patients with nonischemic cardiomyopathy was positively correlated with myocardial inﬂammation and
negatively with IFNb expression and left ventricular ejection fraction.Conclusions PAR2 negatively regulates the innate immune response to CVB3 infection and contributes to myocardial dysfunction.
The antagonism of PAR2 is of therapeutic interest to strengthen the antiviral response after an infection with
a cardiotropic virus. (J AmColl Cardiol 2013;62:1737–45)ª2013by theAmericanCollege of Cardiology FoundationSee page 1746An infection with coxsackievirus B3 (CVB3) induces
viral myocarditis and dilated cardiomyopathy (1). Viral
myocarditis consists of 3 phases: the acute phase with
virus entry and replication; the subacute or virus-clearing
phase involving innate and adaptive immune responses;
and a chronic phase with cardiac remodeling (2). Mice
infected with CVB3 exhibit a disease similar to infected
patients (3).and Pneumology, CharitédUniversitätsmedizin
for Chemistry-Biochemistry, Freie Universität
of Hematology/Oncology, Department of
stitute, University of North Carolina, Chapel
Pharmacology, Ernst-Moritz-Arndt University,
of Molecular Pathology, Institute for Pathology,
Tübingen, Germany; {Department of BiometryA virus infection is initially recognized by Toll-like
receptors (TLR). TLRs are pattern-recognition receptors
and detect conserved motifs of pathogens. TLR3 recog-
nizes double-stranded ribonucleic acid (dsRNA), an inter-
mediate of viral replication. Activation of TLR3 inducesand Clinical Epidemiology, Charité–Universitätsmedizin Berlin, Berlin, Germany; and
the #Institute of Virology, Charité–Universitätsmedizin Berlin, Berlin, Germany. This
study was funded by Deutsche Forschungsgemeinschaft: Sonderforschungsbereich
(SFB/TR 19). The authors have reported that they have no relationships relevant to the
contents of this paper to disclose.
Manuscript received February 15, 2013; revised manuscript received May 13, 2013,
accepted May 13, 2013.
Abbreviations
and Acronyms
AP = activating peptide
CAR = coxsackievirus-
adenovirus receptor
CCL = chemokine ligand
CD = cluster of
differentiation
CVB3 = coxsackievirus B3
DAF = decay-accelerating
receptor




FBS = fetal bovine serum
HL = human leukocyte
IFNb = interferon-beta
IFNg = interferon gamma
IL = interleukin
ko = knockout













pVitro = mock plasmid
P-Stat1 = phospho-signal
transducer and activator of
transcription-1
TLR = Toll-like receptor
TNFa = tumor necrosis
factor-alpha
wt = wild type
Weithauser et al. JACC Vol. 62, No. 19, 2013
PAR2 as a Regulator of Innate Immunity November 5, 2013:1737–45
1738antiviral type 1 interferons, such
as interferon-beta (IFNb) (4).
The protease-activated receptor-2
(PAR2) belongs to a family of
G-protein–coupled receptors,which
are proteolytically activated by
serine proteases (5). After infec-
tion with herpes simplex virus 1,
PAR2 was found to contribute
to virus infectivity (6). Similarly,
Nhu et al. (7) found that PAR2
suppressed TLR3 signaling and
that PAR2 knockout (ko) mice
were protected from inﬂuenza A
virus infections, although another
study (8) found different results.
In addition, PAR2 was shown
to interact with TLR4 and en-
hanceTLR4-dependent signaling
(9,10). Therefore, we analyzed if a
deﬁciency of PAR2 inﬂuences the
development of CVB3-induced
myocarditis and heart failure.Methods
Experimental mouse study.Wild-
type (wt) C57Bl/6 mice and
PAR2ko mice on a C57Bl/6
background (Martin Steinhoff,
Munster, Germany) (11) were
housed at the Forschungsinstitut
für Experimentelle Medizin
(Berlin, Germany). Male mice 6
to 8 weeks old were subdivided
into 4 groups. The mice were
infected intraperitoneally with 1
105 plaque-forming units CVB3
(Nancy Strain) in phosphate-
buffered saline (PBS). As control
subjects, sham infectionswithPBS
were performed (6 to 8 mice/
group) (8 mice/group) for 2, 4, 8,
and 28 days. At 28 days post-infection (p.i.) or post-PBS treatment, mice were anesthetized
with thiopental (125 mg/kg body weight), artiﬁcially ventilated,
and hemodynamically characterized with a 1.2-F micro-
conductance catheter (12). The experiments were performed in
accordance with the National Institutes of Health’s Guide for
the Care and Use of Laboratory Animals (NIH Pub. No. 85-
23, Revised 1996). This study was approved by the Landesamt
für Gesundheit und Soziales (Berlin, Germany; no. G100/04).
Clinical pilot study. Between 2009 and 2010, 72 consecu-
tive patients with clinical symptoms of heart failure such as
dyspnea (New York Heart Association functional classes II to
III) and/or chest pain were included in our pilot study. Thepresence of ischemic heart disease was excluded in all patients
by coronary angiography. All patients underwent an endo-
myocardial biopsy for histological, immunohistological,
and virological examination. The study was approved by
the local ethics committee and performed in accordance
with the ethics principles in the Declaration of Helsinki.
Written informed consent was given by each patient before
participation.
Hemodynamic parameters such as left ventricular ejec-
tion fraction (LVEF) and left ventricular end-diastolic
diameter were determined by angiography and echocardi-
ography. At least 5 endomyocardial biopsies were taken
from each patient by using a ﬂexible bioptome (Westmed,
Tucson, Arizona) (13). The endomyocardial biopsies were
analyzed immunohistologically to assess myocardial in-
ﬂammation markers such as cluster of differentiation (CD)3þ
cells, Mac1, CD45þ cells, human leukocyte (HL) antigen,
intercellular adhesion molecule-1, vascular cell adhesion
molecule-1, and leukocyte function-associated antigen 1.
Cardiac PAR2 and IFNb expression was determined by
quantitative polymerase chain reaction (qPCR). The anal-
ysis was performed in blinded fashion by persons unaware
of patient data. One of the 72 patients was later found to
have amyloidosis and was excluded.
To evaluate the inﬂuence of cardiac PAR2 expression, the
patients were divided into 2 groups according to their PAR2
expression (lower than the median of PAR2 expression,
n ¼ 35; higher than the median, n ¼ 36). Online Table 1
describes the patient characterization.
Cell culture. All cell cultures were maintained in a humidi-
ﬁed atmosphere at 37C and 5% CO2. The cardiomyocytic
HL-1 cell line was kindly provided by Dr. W. C. Claycomb
(Louisiana State University Medical Center, Shreveport,
Louisiana). HL-1 cardiomyocytes were maintained in pre-
coated culture ﬂasks (0.02% gelatin: 12.5 mg/l ﬁbronectin
solution [tebu-bio, Le-Perray-en-Yvelines, France]) in Clay-
combmedium (JRHBiosciences, Lenexa,Kansas)þ 10% fetal
bovine serum (FBS) (PAA Laboratories GmbH, Pasching,
Germany) þ 2 mmol/l l-glutamine (PAA Laboratories
GmbH) þ 100 U/ml penicillin/streptomycin (PAA Labora-
toriesGmbH)þ 0.3mmol/l ascorbic acid (Sigma-Aldrich, St.
Louis, Missouri) and 10 mmol/l norepinephrine (Sigma-
Aldrich).
Primary cardiomyocytes and cardiac ﬁbroblasts were
isolated from embryonic mouse hearts (embryonic day 13.5)
and were maintained in Dulbecco modiﬁed Eagle medium
(DMEM) without L-glutamine (cardiomyocytes)/DMEMþ
L-glutamine (ﬁbroblasts) (PAA Laboratories GmbH þ 10%
FBS þ 100 U/ml penicillin/streptomycin. Fibroblasts were
used for experiments until the ﬁfth passage (14).
Overexpression of PAR2. Cardiac ﬁbroblasts were tran-
siently transfected with a mock plasmid (pVitro) and
a plasmid containing PAR2 (PAR2pVitro) using Lipofect-
amine 2000 (Invitrogen, Grand Island, New York).
In vitro stimulation. For infection experiments, primary
cells were exposed to CVB3 at a multiplicity of infection of
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17391 in basal DMEM. Thirty minutes after infection, the
medium was aspirated and fresh growth medium was added.
In replication experiments, a neutralizing anti-mouse-IFNb
(10 mg/ml) (BioLegend, San Diego, California) was added
to the medium.
Stimulation with a PAR2 agonist 200 mmol/l 2f-
LIGRLO-amide (Calbiochem, San Diego, California),
which is designated as an activating peptide (AP), and with
a TLR3 agonist polyinosinic:polycytidylic acid (poly[I:C])
(10 mg/ml) (IMGENEX, San Diego, California) was per-
formed in basal DMEM after starvation overnight in
DMEM þ 0.5% FBS.
Immunohistochemistry. Murine tissue of the left ventricle
was embedded in Tissue-Tek (Dako, Glostrup, Denmark).
Immunohistochemistry was performed with antibodies
against CD3 (1:75; Santa Cruz, Dallas, Texas) and CD68
(1:500; Abcam, Cambridge, Massachusetts). For hematox-
ylin and eosin staining and in situ hybridization for detection
of viral RNA, parafﬁn-embedded tissue sections were used.
The staining procedure and in situ hybridization was per-
formed as previously described (3,15). Images were taken on
a Leica microscope (LeicaMicrosystems,Wetzlar, Germany)Figure 1 Virus Distribution and Replication in wt and PAR2ko Mice
(A) The viral genome in pancreas, (B) liver, and (C) spleen was analyzed with quantitative
assays of wild type (wt) and protease-activated receptor 2 (PAR2) knockout (ko) hearts at
ribonucleic acid (mRNA) expression and plaque forming units (pfu) from an individual mou
and 8 day p.i. (F) In situ hybridization of the minus or replicating strand in hearts at 8 days
for PAR2ko versus respective wt.and quantiﬁcations done with the Lucia software (Lucia
Cytogenetics, Prague, Czech Republic).
Plaque assay,Western blot analysis, immunoprecipitation,
and real-time PCR. Plaque assay, Western blot, and immu-
noprecipitation analysis are described elsewhere (15–17).
Speciﬁc antibodies were used for: phospho-signal transducer
and activator of transcription (P-Stat)1 (Abcam); glycerin-
aldehyd-3-phosphat-dehydrogenase (Calbiochem), and beta-
actin (Santa Cruz); PAR2 (3 mg, clone S-19; Santa Cruz);
TLR3(Abcam); andTLR4(IMGENEX).For real-timePCR,
gene expression was determined with TaqMan PCR using
6-carboxyﬂuorescein phosphoramidite TaqMan gene expres-
sion assays (Applied Biosystems, Invitrogen): tumor necrosis
factor (TNF) Mm00443258_m1; interleukin (IL) 1b-
Mm00434228_m1; interferon (IFN) g-Mm00801778_m1;
chemokine ligand (CCL) Mm00441243_g1; CCL5 Mm
01302428_m1; IFNb Mm00446190_m1; IL6 Mm0044
6190_m1; coxsackievirus-adenovirus receptor (CAR) Mm
00438361_m1; decay-accelerating factor (DAF) Mm00438377.
Relative gene expression was determined with the compar-
ative C(t) (DDCt) method with 18sRNA Hs99999901_s1
as endogenous control.at 2, 4, and 8 Days p.i. With CVB3
polymerase chain reaction (qPCR) at 2 and 4 days (d) post-infection (p.i.). (D) Plaque
4 and 8 days p.i. Each symbol represents the coxsackievirus B3 (CVB3) messenger
se. (E) In situ hybridization of CVB3 plus strand genome of wt and PAR2ko mice at 4
p.i. (E, F) There are 6 to 8 mice for each time point. Scale bar ¼ 100 mm. *p < 0.05
Figure 2 Up-Regulation of IFNb Expression and IFNb-Related Pathways in PAR2ko Mice
Interferon-beta (IFNb) expression from infected and control (co) (A) pancreas, (B) livers, and (C) hearts measured by qPCR. (A, B) Expression levels are fold to wt at 2 days p.i.
(mean was set to 1). (C) Expression levels are fold to wt co (mean was set to 1). Data are mean  SEM (n ¼ 6 to 8 mice/group). *p < 0.05 for PAR2ko versus wt, yp < 0.05 for
PAR2ko versus co mice of the respective genotype and p value according to nonparametric Brunner modeling of longitudinal data. (D) Representative Western blot from infected
and co hearts shows phospho-signal transducer and activator of transcription-1 (P-Stat1) and beta-actin (b-actin) at 8 days p.i. Abbreviations as in Figure 1.
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1740Statistical analysis. Descriptives include absolute and rela-
tive frequencies for categorical variables, and mean  SD for
quantitative variables. Due to lack of normality of most the
measurements, the Mann-Whitney U test or the Wilcoxon
signed rank test have been performed for pairwise comparisons
between 2 independent groups or between 2 individual time
points, respectively. For longitudinal data analyses, the
nonparametric model developed by Brunner et al. (18) has
been used, with the genotype as the interindividual factor and
the different time points as the intra-individual factor. All
statistical analyses have been performed using the commer-
cially available software SPSS (version 21, SPSS Inc., Chicago,
Illinois), SAS (version 9.3, SAS Institute, Cary, North
Carolina), and/or GraphPad Prism (version 5, San Diego,
California). Any p values <0.05 are considered statistically
signiﬁcant. No Bonferroni correction has been applied.Results
Reduction of virus load in the absence of PAR2. Similar
levels of CVB3 were observed in wt and PAR2ko pancreas,
liver, and spleen 2 days p.i., whereas the level of CVB3
genomes was signiﬁcantly lower 4 days p.i. in PAR2ko
than in wt pancreas (Fig. 1A). No signiﬁcant differences in
CVB3 genomes were observed in wt and PAR2ko livers and
spleens (Figs. 1B and 1C). Plaque assays of a CVB3-infectedheart revealed a lower virus load in PAR2ko than in wt
hearts at 4 days and 8 days p.i. (Fig. 1D). In situ hybrid-
ization showed more positive signals for the plus (genomic)
strand of the CVB3 genome in wt than in PAR2ko hearts
(Fig. 1E). Sites active of virus replication were evident in
wt hearts 8 days p.i. No minus strands were detectable in
PAR2ko hearts (Fig. 1F).
CVB3 enters the cell via the CAR (19). CAR messenger
ribonucleic acid (mRNA) was signiﬁcantly increased in wt
hearts compared with PAR2ko hearts at 4 days p.i. (Online
Fig. 1A). The expression of DAF, a coreceptor for CAR,
was also signiﬁcantly lower in PAR2ko mice than in wt mice
at 4 days p.i. (Online Fig. 1B). The baseline expression of
CAR and DAF was similar in wt and PAR2ko mice
(Online Figs. 1A and 1B).
Increased IFNb expression in PAR2ko mice. IFNb is an
important early antiviral cytokine that is used to combat
CVB3 infection. IFNb expression was below detection levels
in the pancreas and liver of uninfected PAR2ko and wt
mice. At 2 days p.i., the pancreas and liver of PAR2ko mice
exhibited a higher IFNb expression than those of wt mice
did (Figs. 2A and 2B). Hearts of uninfected PAR2ko had
a 5-fold higher IFNb expression than wt hearts did
(Fig. 2C). Reﬂecting the virus replication, cardiac IFNb
expression was increased in wt mice at 4 days p.i., but not in
infected PAR2ko mice (Fig. 2C).
Figure 3 Less Immune Cell Inﬁltration and Cytokine Expression in PAR2ko Hearts Post-Infection
Hematoxylin and eosin staining of wt and PAR2ko cardiac tissue from co mice and mice at 8 days p.i. (A) Arrows indicate immune cell inﬁltration and tissue damage after CVB3
infection (scale bar ¼ 100 mm). (B) Quantiﬁcation of staining for CD68þ and (C) CD3þ cells at 8 days p.i. (D to I) Expression of (D) TNFa, (E) IL6, (F) IL1b, (G) CCL2, (H) CCL5,
and (I) IFNg. Expression levels are fold to wt co (mean was set to 1). Data are mean  SEM (n ¼ 6 to 8 mice/group). *p < 0.05 for PAR2ko versus wt and p value according to
nonparametric Brunner modeling of longitudinal data. CCL ¼ chemokine ligand; CD ¼ cluster of differentiation; IL ¼ interleukin; TNF ¼ tumor necrosis factor; other abbreviations
as in Figures 1 and 2.
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1741IFNb signaling induces Stat1 phosphorylation. The level
of phosphorylated Stat1 was higher in PAR2ko than in wt
hearts before infection (Fig. 2D). At 8 days p.i., P-Stat1 was
increased in wt and PAR2ko hearts.
PAR2 modulates the immune response. PAR2ko exhi-
bited almost no inﬂammatory cell inﬁltration and tissue
damage after CVB3 infection (Fig. 3A). Signiﬁcantly fewer
CD68þ and CD3þ cells were seen in PAR2ko than in wt
hearts (Figs. 3B and 3C). Additionally, cytokine and
chemokine levels were signiﬁcantly higher in wt than in
PAR2ko hearts at 4 and 8 days p.i. (Figs. 3D to 3H).
Interferon gamma (IFNg) mRNA expression was different
between the 2 groups at 8 days p.i. but not at 4 days p.i.
(Fig. 3I). Over time, both wt and PAR2ko mice showed
a signiﬁcant increase in cytokine expression after infectionversus baseline levels, respectively. However, the cytokine
expression was always increased to a signiﬁcantly higher level
in wt compared with PAR2ko mice.
PAR2 deﬁciency protects from CVB3-induced heart
failure. A signiﬁcantly reduced left ventricular function was
found in the wt animals at 28 days p.i. compared with left
ventricular function at baseline. In contrast, compared with
the uninfected mice, the PAR2ko mice exhibited no
reduction in heart function at 28 days p.i. The cardiac output
was signiﬁcantly better in PAR2ko than in wt mice at
28 days p.i. (Online Table 2).
Increased IFNb expression and Stat1 phosphorylation in
PAR2ko cardiac ﬁbroblasts. Basal IFNb expression of
primary cardiac ﬁbroblasts was 2.5-fold higher in PAR2ko
than in wt ﬁbroblasts. IFNb expression was also higher in
Figure 4 PAR2 Reduces TLR3-Dependent IFNb and Stat1 Phosphorylation in Cardiac Fibroblasts
(A) IFNb expression from wt and PAR2ko cardiac ﬁbroblasts infected with 1 multiplicity of infection CVB3 and (B) stimulated with 10 mg/ml polyinosinic:polycytidylic acid
(poly[I:C]) for 6 h. (C) CCL5 expression from wt and PAR2ko cardiac ﬁbroblasts stimulated with 10 mg/ml poly(I:C) for 6 h. Expression levels are fold to wt co (mean was set to
1) (n ¼ 3, performed in duplicates). *p < 0.05 for PAR2ko versus wt. yp < 0.05 for PAR2ko versus co cells of the respective genotype and p value according to nonparametric
Brunner modeling of longitudinal data. (D to F) Representative Western blots show phosphorylation for Stat1 in wt and PAR2ko ﬁbroblasts (D) before and (E) after poly(I:C)
stimulation for 6 h and (F) 24 h (n ¼ 3). Gapdh ¼ glycerinaldehyd-3-phosphat-dehydrogenase; TLR ¼ Toll-like receptor; other abbreviations as in Figures 1 and 2.
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1742PAR2ko than in wt cells after infection with CVB3
(Fig. 4A). Stimulation with the dsRNA analog poly(I:C)
induced IFNb expression in wt and PAR2ko ﬁbroblasts with
signiﬁcantly higher levels in PAR2ko ﬁbroblasts (Fig. 4B).
Poly(I:C) induced the expression of the IFNb-regulated
gene CCL5 in wt and PAR2ko ﬁbroblasts. As seen for
IFNb, CCL5 mRNA levels were higher in PAR2ko than in
wt cells (Fig. 4C). Consistent with our ﬁndings in PAR2ko
hearts, a higher baseline phosphorylation of Stat1 was
observed in PAR2ko ﬁbroblasts compared with wt ﬁbro-
blasts (Fig. 4D). Stimulation with poly(I:C) for 6 h led to
more Stat1 phosphorylation in PAR2ko compared with wt
ﬁbroblasts (Fig. 4E). P-Stat levels were also higher at 24 h in
stimulated PAR2ko ﬁbroblasts than in wt cells (Fig. 4F).
Virus replication was analyzed 6 and 24 h after infection of
PAR2ko and wt cardiomyocytes with CVB3. As seen in mice,
compared with wt cardiomyocytes, PAR2ko exhibited a lower
virus load 6 and24hp.i. Importantly, the virus load inPAR2ko
cardiomyocytes increased signiﬁcantly, and the difference
between virus load in the PAR2ko and wt cardiomyocytes was
abrogated by a neutralizing IFNb antibody (Online Fig. 2).
PAR2 activation reduces TLR3-dependent IFNb
expression. To analyze the mechanism by which PAR2
regulates IFNb expression, PAR2ko primary ﬁbroblasts
were transfected with an empty or a PAR2-containing
plasmid. PAR2 overexpression in PAR2-deﬁcient ﬁbro-
blasts reduced the IFNb expression compared with cells
transfected with the empty vector (Fig. 5A). Furthermore,
mock- and PAR2-transfected cells were stimulated for 2 and24 h with poly(I:C) and/or AP, respectively. Stimulation of
PAR2 alone did not affect Stat1 phosphorylation in mock-
and PAR2-transfected cells, whereas the level of P-Stat1
was strongly increased upon treatment with poly(I:C) in
both cell types. Activation with AP and poly(I:C) simulta-
neously did not affect the P-Stat1 level in mock transfected
cells. However, Stat1 phosphorylation was markedly reduced
in PAR2 transfected cells treated with the AP and poly(I:C)
(Fig. 5B), which is consistent with a PAR2-dependent
inhibition of the TLR3 pathway.
Previous studies have shown that PAR2 binds to TLR4
(9). Therefore, we determined if PAR2 physically interacted
with TLR3 and TLR4. HL-1 cells were transiently trans-
fected to overexpress PAR2. Cell extracts were immuno-
precipitated with an anti-PAR2 antibody and levels of TLR3
within the complex measured by Western blotting. TLR3
and TLR4 were only observed in cells that overexpressed
PAR2 and were stimulated with AP (Figs. 5C and 5D).
Myocardial PAR2 expression correlates with the IFNb
expression, myocardial inﬂammation, and LVEF in
patients with cardiomyopathy. Patients with nonischemic
cardiomyopathy were divided into 2 groups according to the
median cardiac PAR2 expression in the whole study pop-
ulation. IFNb expression was higher in patients with low
PAR2 expressions (Fig. 6A). Patients with a PAR2 mRNA
expression above the median had more myocardial inﬁltrates
(Figs. 6B to 6D) and showed a signiﬁcantly lower LVEF
than did patients with a PAR2 expression below the median
(Figs. 6E and 6F).
Figure 5 PAR2 Reduces TLR3-Dependent IFNb and Stat1 Phosphorylation in Cardiac Fibroblasts
(A) IFNb expression in mock plasmid (pVitro)- and PAR2pVitro-transfected PAR2ko ﬁbroblasts. Data are fold to pVitro (mean was set to 1). Data are mean  SEM (n ¼ 3,
performed in duplicates). *p < 0.05 for PAR2ko versus wt. (B) Representative Western blots for phosphorylation of Stat1 in pVitro- and PAR2pVitro-transfected PAR2ko
ﬁbroblasts before and after stimulation with 200 mmol/l activating peptide (AP) and/or 10 mg/ml poly(I:C) for 2 and 24 h (n ¼ 3). (C, D) pVitro- or PAR2pVitro-transfected mouse
cardiomyocytic cell line (HL)-1 were stimulated with 200 mmol/l AP for 1 h. Representative Western blots show (C) TLR3 and (D) TLR4 after PAR2-immunoprecipitation.
Densitometry of (C) TLR3 and (D) TLR4 bands is presented as fold of unstimulated control cells  SEM. *p < 0.05 (n ¼ 3, performed in duplicates). Abbreviations as in
Figures 1, 2, and 4.
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The study shows that PAR2ko mice are protected from
CVB3-induced myocarditis. This was associated with an
elevated IFNb expression in PAR2ko hearts and cardiac
ﬁbroblasts. A direct interaction between PAR2 and TLR3
was observed. The PAR2 expression in endomyocardial
biopsies of patients with nonischemic cardiomyopathy was
positively correlated to myocardial inﬂammation and nega-
tively with the IFNb expression and the LVEF.
PAR2 and virus infections. An important ﬁnding of this
study is that PAR2 contributes to virus infection and severe
myocarditis. In line with our data, Nhu et al. (7) observed
a higher resistance of PAR2ko mice to inﬂuenza-induced
pathology than was found with wt mice. In contrast,
higher levels of the PAR2 activating enzyme trypsin caused
a more severe inﬂuenza-induced myocarditis (20).
The CAR expression was increased in hearts of wt mice in
contrast to protected PAR2ko mice at 4 days p.i. Similarly,Fuse et al. (21) reported that Myd88ko mice, which were
protected from CVB3-induced myocarditis, also exhibited
a reduced myocardial CAR expression.
Due to reduced virus levels and inﬂammation, the left
ventricular function was not altered in PAR2ko hearts at 28
days p.i.. In contrast, severe deterioration of myocardial
contractility was observed in wt animals. In summary, our
in vivo results clearly demonstrate that PAR2 is critical for
the development of CVB3-induced myocarditis.
PAR2, the IFNb pathway, and TLR. A former study
demonstrated that IFNbko mice had more severe myocar-
ditis than wt mice did (22). Therapeutic treatment with
IFNb reduced the virus load of CVB3-infected mice (23). In
our study, the basal IFNb levels were signiﬁcantly increased
in PAR2ko hearts and ﬁbroblasts. Furthermore, the over-
expression of PAR2 reduced the enhanced basal expression
of IFNb in PAR2ko ﬁbroblasts.
IFNb signaling induces Stat1 phosphorylation (7), which
was basally increased in the absence of PAR2. Given that
Figure 6
Cardiac PAR2 Expression in Patients With Cardiomyopathy Is Associated With Increased Cardiac Inﬂammation,
Decreased IFNb Expression, and Reduced LVEF
(A) Differences in myocardial IFNb expression and (B to D) CD3þ, leukocyte function-associated antigen (LFA)þ and CD45þ cells dependent on low and high myocardial PAR2
expression. (E, F) Relations between myocardial PAR2 expression and left ventricular ejection fraction (LVEF) or (F) left ventricular end-diastolic diameter (LVEDD). Data are
expressed as mean  SEM. *p < 0.05 low versus high PAR2 expression. Abbreviations as in Figures 1 and 3.
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1744neutralizing IFNb abrogated the diminished virus replica-
tion in PAR2ko cardiomyocytes, the basally activated IFNb
pathway is likely to be a reason why less virus replication and
inﬂammation were observed in PAR2ko mice. In summary,
PAR2 reduces IFNb expression and the antiviral immune
response.
IFNb expression is regulated by TLR. In particular by
TLR3, which recognizes dsRNA (4). A higher mortality
was found in absence of TLR3 upon infection with CVB3
(24). Rallabhandi et al. (9) discovered an AP-dependent
physical interaction between PAR2 and TLR4. We found
TLR3 co-immunoprecipitated with PAR2 after PAR2
activation with AP. Thus, PAR2 activation can diminish
the antiviral response. The physical interaction of PAR2
with TLR3 seems to reduce TLR3-mediated signaling
(Online Fig. 3).
PAR2 expression in human heart failure. In a former
clinical study with enterovirus- or adenovirus-positive
patients, treatment with IFNb eliminated the virus from
the myocardium and improved hemodynamic function
(25). PAR2 deﬁciency also improved the cardiac function
in an ischemia/reperfusion injury model (26). To date,
a relationship among PAR2 expression, myocardial func-
tion, and inﬂammation in patients is unknown. In a ﬁrst
pilot study on patients with cardiomyopathy, the myocardial
PAR2 expression was negatively associated with the
myocardial IFNb expression and the LVEF. In contrast,a positive association was discovered for PAR2 and different
inﬂammatory markers. Whether the PAR2 expression in
the heart is predictive for myocardial inﬂammation and
dysfunction in patients with cardiomyopathy remains to be
studied.
Conclusions
Cardiac PAR2 is crucial for the genesis of CVB3-induced
myocarditis. PAR2 physically interacts with TLR3 and
regulates TLR3-dependent IFNb production in response to
an enterovirus infection.
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